Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Members & Subscribers
    • Benefits for CMA Members
    • CPD Credits for Members
    • Subscribe to CMAJ Print
    • Subscription Prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Members & Subscribers
    • Benefits for CMA Members
    • CPD Credits for Members
    • Subscribe to CMAJ Print
    • Subscription Prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
Review

Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection

David N. Juurlink
CMAJ April 27, 2020 192 (17) E450-E453; DOI: https://doi.org/10.1503/cmaj.200528
David N. Juurlink
Division of Clinical Pharmacology and Toxicology, Sunnybrook Health Sciences Centre; Departments of Medicine and Pediatrics, University of Toronto; ICES; Ontario Poison Centre, Toronto, Ont.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Related Content
  • Responses
  • Metrics
  • PDF
Loading
KEY POINTS
  • Chloroquine and hydroxychloroquine are generally well tolerated, but clinicians and patients should be aware of serious adverse events that can occur, even during short courses of treatment.

  • Potential risks of treatment include prolongation of the QTc interval (especially in patients with preexisting cardiac disease or if coprescribed with azithromycin), hypoglycemia, neuropsychiatric effects, drug–drug interactions and idiosyncratic hypersensitivity reactions.

  • Genetic variability in metabolism of these drugs is considerable and influences their safety and effectiveness.

  • Chloroquine and hydroxychloroquine are extremely toxic in overdose.

  • As we await stronger evidence on the role, if any, of these drugs in the treatment or prevention of coronavirus disease 2019, uncommon but serious harms of treatment can be mitigated by careful patient selection and monitoring.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread rapidly around the globe in recent months. With deaths from its associated disease, coronavirus disease 2019 (COVID-19), projected to reach into the millions and a vaccine unlikely in the near term, the search is on for existing drugs that might prevent COVID-19 or improve outcomes for patients who have COVID-19. Chloroquine and its derivative hydroxychloroquine, which have been used for decades in the treatment and prevention of malaria as well as chronic inflammatory diseases such as rheumatoid arthritis and systemic lupus erythematosus, have received much attention as potential therapies.

Optimism for repurposing these drugs stems from 2 lines of evidence: inhibition of Coronaviridae (including SARS and SARS-CoV-2) in vitro1–3 and preliminary but contradictory clinical data from studies conducted in China and France.4–8 Of these, an open-label nonrandomized study by Gautret and colleagues5 that involved treatment using hydroxychloroquine (combined in some patients with azithromycin, an azalide antibiotic with putative antiviral properties9) has garnered an unusual degree of attention. Despite this study’s small sample size and serious methodologic limitations, on Mar. 21, 2020, President Donald Trump touted the drug combination as having “… a real chance of being one of the biggest game-changers in the history of medicine.”10 Within days of this pronouncement, chloroquine-related deaths were reported in Africa and Arizona (www.theguardian.com/world/2020/mar/24/coronavirus-cure-kills-man-after-trump-touts-chloroquine-phosphate; www.cnn.com/2020/03/23/africa/chloroquine-trump-nigeria-intl/index.html).

As we await further evidence on the role, if any, of these drugs in addressing the SARS-CoV-2 pandemic, many clinicians have already begun using them to treat COVID-19. The most typical regimen is 5 days of hydroxychloroquine at daily doses of 400–600 mg, which delivers a cumulative dose comparable to what might be given over 48 hours for chloroquine-sensitive malaria caused by Plasmodium falciparum. The US Food and Drug Administration has granted emergency authorization for the use of chloroquine and hydroxychloroquine for treatment of COVID-19,11 and the Indian Council of Medical Research COVID-19 National Task Force has advocated extended hydroxychloroquine prophylaxis for health care workers.12

This review provides a general overview of potential harms associated with use of chloroquine and hydroxychloroquine — and to a lesser extent azithromycin — and a discussion of the management of adverse events, based on best available evidence (Box 1).

Box 1:

Evidence used in this review

A search of PubMed from 1966 until 2020 was conducted for publications related to adverse events involving chloroquine, hydroxychloroquine and azithromycin. No restrictions were placed on article type; however, reviews were prioritized where available and their bibliographies were examined for articles that might have been missed in the broader search.

What are the potential adverse effects of chloroquine or hydroxychloroquine and azithromycin?

Along with common adverse effects such as pruritus, nausea and headache, chloroquine and hydroxychloroquine can predispose patients to life-threatening arrhythmias, an effect that may be enhanced by concomitant use of azithromycin. Other uncommon but serious potential harms include hypoglycemia, neuropsychiatric effects, idiosyncratic hypersensitivity reactions and drug–drug interactions, with genetic variability playing an important role in each of these. Chloroquine and hydroxychloroquine are also extremely toxic in overdose.

Prolongation of the QTc interval

Both chloroquine and hydroxychloroquine interfere with ventricular repolarization, leading to prolongation of the QTc interval and an increased risk of torsades de pointes (TdP). This effect is dependent on dose: studies involving volunteers found mean increases in QTc of 6.1 ms after a dose of 600 mg and 28 ms after a dose of 1200 mg.13,14 However, the effect varies among individuals and can be pronounced. Among 30 children given short courses of chloroquine for malaria, 1 experienced an increase in the QTc interval of 64 ms after just 1 day of treatment.15

Azithromycin itself does not usually cause clinically significant prolongation of the QTc interval,16 but its use in combination with either chloroquine or hydroxychloroquine could theoretically increase the risk of TdP. Reassuringly, an animal model found no evidence of such an interaction,17 and the combination has been used safely in patients with malaria.18,19 Nevertheless, given limited experience in patients with COVID-19 and the potential for use of these drugs in patients with cardiac disease or those taking other drugs that delay repolarization, monitoring of the QTc interval at baseline and daily for the duration of treatment is advised, especially if azithromycin is coprescribed. Daily monitoring is impractical during prophylactic treatment, but assessment of the QTc interval at baseline is advised, especially for individuals with cardiac disease. It is prudent to correct electrolyte disorders and, where possible, avoid or minimize use of other drugs known to prolong the QT interval (Box 2).

Box 2:

Useful resources for clinicians

  • The University of Liverpool COVID-19 Drug Interactions website (https://www.covid19-druginteractions.org/).

  • The Department of Medicine at the University of Indiana supports a resource to help clinicians anticipate potentially harmful drug interactions (https://drug-interactions.medicine.iu.edu/MainTable.aspx).

  • The Credible Meds website (www.crediblemeds.org/) is a resource to help physicians identify other drugs that may prolong the QT interval.

Hypoglycemia

Case reports have described severe hypoglycemia with both chloroquine and hydroxychloroquine in patients with malaria as well as those with lupus and other chronic diseases.20–23 The basis of this effect (aside from malaria-related hypoglycemia) is multifactorial and includes reduced insulin clearance, increased insulin sensitivity and enhanced pancreatic insulin release.24 Among 250 patients with poorly controlled type 2 diabetes who were unwilling to start insulin, hydroxychloroquine (400 mg/d) was associated with marked reductions in fasting plasma glucose, hemoglobin A1c and body weight, whereas hypoglycemia developed in 2% of participants over the 48-month study period.25

Physicians should warn patients who are being treated with chloroquine or hydroxychloroquine about the possibility of hypoglycemia and describe its manifestations. Management of hypoglycemia involves cessation of the drug and administration of supplemental glucose or parenteral dextrose as needed. For patients with severe or recurrent hypoglycemia, octreotide (50–100 μg administered intravenously or subcutaneously every 8 h) is a well-tolerated somatostatin analogue that inhibits pancreatic insulin release and may be helpful in mitigating the rebound hyperinsulinemia than can ensue after large doses of intravenous dextrose.26

Neuropsychiatric effects

Chloroquine and hydroxychloroquine are known to cause a wide spectrum of neuropsychiatric manifestations, including agitation, insomnia, confusion, mania, hallucinations, paranoia, depression, catatonia, psychosis and suicidal ideation.27 These can occur at all ages,28 during acute or chronic use,29–32 and in patients with and without a history of mental illness.28,32 Resolution is expected upon stopping the drug, although symptoms may not resolve quickly.33 Patients and clinicians should recognize new or worsening neuropsychiatric symptoms as possible adverse effects of treatment. Indeed, given the speculative nature at present of antimalarial agents in the prevention or treatment of SARS-CoV-2 infection, an argument can be made for avoiding these drugs in patients with underlying mental illness until more data are available.

Hematologic toxicities

Many clinicians associate antimalarial agents with oxidative hemolysis, particularly in patients with severe variants of glucose-6-phosphate dehydrogenase (G6PD) deficiency. Primaquine is well known to cause this, but chloroquine and hydroxychloroquine are less likely to do so. In a chart review of 275 rheumatology patients of whom 11 were documented to have G6PD deficiency, no episodes of hydroxychloroquine-related hemolysis were identified over more than 700 months of treatment.34 Hematologic abnormalities including lymphopenia, eosinophilia and atypical lymphocytosis can be features of immunologically mediated idiosyncratic drug reactions, as discussed below.

Genetic variability

Both chloroquine and hydroxychloroquine are metabolized by hepatic cytochrome P450 enzyme 2D6 (CYP2D6), the expression of which varies among individuals as the result of genetic polymorphisms. 35,36 Roughly 7% of white North Americans have no functional CYP2D6 (the “poor metabolizer” phenotype) and 1%–2% have gene duplications conferring an “ultrarapid metabolizer” phenotype, although the prevalence of these varies based on ethnicity.37 This genetic variability influences the response to treatment for malaria and chronic inflammatory diseases, as well as the risk of adverse events.38,39

Drug–drug interactions

In addition to being substrates for CYP2D6, chloroquine and hydroxychloroquine inhibit its activity, most likely by competitive inhibition.40 This has the potential to influence the fate of other drugs reliant on CYP2D6 for metabolism. For instance, hydroxychloroquine increases systemic exposure to orally administered metoprolol levels by about 65% and peak concentrations by 72%.41 Although data are limited, it is reasonable to assume that chloroquine and hydroxychloroquine potentiate other CYP2D6 substrates (including carvedilol and many others), and undermine the effectiveness of prodrugs reliant on CYP2D6 for activation such as codeine and tramadol.42 Indeed, the potential exists for chloroquine and hydroxychloroquine to precipitate opioid withdrawal in patients who are taking these drugs regularly.

Unlike the related drugs erythromycin and clarithromycin, azithromycin exhibits little inhibition of cytochrome P450 enzymes or drug-transport proteins such as P-glycoprotein.43 As such, azithromycin is far less likely to precipitate clinically important drug–drug interactions (Box 2).

Immunologically mediated adverse reactions

Chloroquine and hydroxychloroquine have been implicated in severe cutaneous adverse reactions, including Stevens–Johnson syndrome,44 toxic epidermal necrolysis,45,46 DRESS (drug reaction with eosinophilia and systemic symptoms)47,48 and others. Although rare, these entities should be considered in patients with new-onset fever, exanthem or mucositis in the weeks after the start of treatment, particularly when accompanied by new hematologic abnormalities (such as lymphopenia, eosinophilia or atypical lymphocytosis) or unexplained liver or kidney injury.

Other safety concerns

There is no evidence that chloroquine, hydroxychloroquine or azithromycin are harmful to the developing fetus, and pregnancy is not a contraindication to their use.49,50 Long-term risks of treatment include retinopathy, vacuolar myopathy, neuropathy, restrictive cardiomyopathy and cardiac conduction disturbances. 51–53 These risks are negligible in the context of treatment of SARS-CoV-2 but may be relevant if they are used for extended prophylaxis.

Overdose

Chloroquine and hydroxychloroquine are extremely toxic in overdose, sharing several manifestations in common with cyclic antidepressant poisoning. Deliberate or inadvertent overdose leads to rapid onset of central nervous system toxicity (seizures and coma), cardiovascular collapse (including inhibition of cardiac sodium and potassium channels resulting in QRS widening and QT interval prolongation, respectively) and hypokalemia resulting from intracellular shifting.54 Treatment of overdose is largely supportive and includes prompt administration of activated charcoal, intravenous benzodiazepines and vasopressors as needed, sodium bicarbonate or hypertonic saline for substantial QRS widening and related arrhythmias, and judicious management of hypokalemia while taking care to avoid overcorrection. Urgent consultation with a poison control centre is advised in all cases.

Could use of these drugs potentially worsen COVID-19?

Despite optimism (in some, even enthusiasm) for the potential of chloroquine or hydroxychloroquine in the treatment of COVID-19, little consideration has been given to the possibility that the drugs might negatively influence the course of disease. For example, some have speculated that inhibition of T-helper cell proliferation and interleukin-2 production or responsiveness might inadvertently augment the inflammatory response in patients who are infected, negatively influencing patient outcomes.55 Although somewhat counterintuitive, the possibility that these drugs might adversely influence outcomes underscores the urgent need for high-quality randomized controlled trials in the face of a growing pandemic.56

Could use of these drugs to treat or prevent COVID-19 lead to shortages for other patients?

The immunomodulatory effects of hydroxychloroquine are critical to a subset of patients with systemic lupus erythematosus, rheumatoid arthritis, ankylosing spondylitis, sarcoidosis and other chronic diseases. A surge in prescriptions based on speculation about their role in the prevention or treatment of SARS-CoV-2 infection threatens the availability of these drugs for patients with chronic inflammatory disorders for whom they are known to be effective. At least 2 manufacturers have announced plans to increase hydroxychloroquine production in anticipation of this need.56

Conclusion

The use of either chloroquine or hydroxychloroquine and azithromycin for treatment or prevention of SARS-CoV-2 infection is currently supported primarily by in vitro data and weak studies involving humans. Physicians and patients should be aware of several uncommon but potentially life-threatening adverse effects should these drugs be used before better-designed studies determine their benefit, if any, in treating or preventing COVID-19. Harms of treatment can be mitigated by careful patient selection and monitoring.

Acknowledgments

The author thanks Bryan Hayes, Moira Kapral, Todd Lee, Andrew Morris and Mark Yarema for helpful suggestions on earlier versions of this manuscript.

Footnotes

  • Competing interests: None declared.

  • This article was solicited and has not been peer reviewed.

  • Funding: None.

References

  1. ↵
    1. Vincent MJ,
    2. Bergeron E,
    3. Benjannet S,
    4. et al
    . Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J 2005;2:69.
    OpenUrlCrossRefPubMed
    1. Wang M,
    2. Cao R,
    3. Zhang L,
    4. et al
    . Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020;30: 269–71.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Yao X,
    2. Ye F,
    3. Zhang M,
    4. et al
    . In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis 2020 Mar. 9 [Epub ahead of print]. pii: ciaa237. doi:10.1093/cid/ciaa237.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Gao J,
    2. Tian Z,
    3. Yang X
    . Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends 2020;14:72–3.
    OpenUrlCrossRefPubMed
  4. ↵
    1. Gautret P,
    2. Lagier JC,
    3. Parola P,
    4. et al
    . Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 2020 Mar. 20:105949 [Epub ahead of print]. doi:10.1016/j.ijantimicag.2020.105949.
    OpenUrlCrossRefPubMed
    1. Chen J,
    2. Liu D,
    3. Liu L,
    4. et al
    . A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19). J Zhejiang Univ (Med Sci) 2020;49. doi:10.3785/j.issn.1008-9292.2020.03.03.
    OpenUrlCrossRef
    1. Chen Z,
    2. Hu J,
    3. Zhang Z,
    4. et al
    . Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. medRxiv 2020 Mar. 31. doi:https://doi.org/10.1101/2020.03.22.20040758.
  5. ↵
    1. Molina JM,
    2. Delaugerre C,
    3. Goff JL,
    4. et al
    . No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection. Med Mal Infect 2020 Mar. 30 [Epub ahead of print]. pii: S0399-077X(20)30085-8. doi: 10.1016/j.medmal.2020.03.006.
    OpenUrlCrossRefPubMed
  6. ↵
    1. Li C,
    2. Zu S,
    3. Deng YQ,
    4. et al
    . Azithromycin protects against Zika virus infection by upregulating virus-induced type I and III interferon responses. Antimicrob Agents Chemother 2019 Sept. 16 [Epub ahead of print]. pii: AAC.00394-19. doi:10.1128/AAC.00394-19.
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Trump DJ
    . HYDROXYCHLOROQUINE & AZITHROMYCIN, taken together, have a real chance to be one of the biggest game changers in the history of medicine. The FDA has moved mountains … [Tweet] 2020 Mar. 21. Available: https://twitter.com/realdonaldtrump/status/1241367239900778501?lang=en (accessed 2020 Apr. 3).
  8. ↵
    1. Hinton D
    . Re: Request for emergency use authorization for use of chloroquine phosphate or hydroxychloroquine sulfate supplied from the strategic national stockpile for treatment of 2019 Coronavirus disease [response letter to Bright R]. Washington (DC): United States Food and Drug Administration; 2020 Mar. 28. Available: www.fda.gov/media/136534/download (accessed 2020 Apr. 1).
  9. ↵
    Web Service Desk. What is hydroxychloroquine, the drug recommended by ICMR? Indian Express [New Delhi]. Available: https://indianexpress.com/article/what-is/what-is-hydroxychloroquine-coronavirus-covid-19-6329181/ (accessed 2020 Apr. 3).
  10. ↵
    1. Mzayek F,
    2. Deng H,
    3. Mather FJ,
    4. et al
    . Randomized dose-ranging controlled trial of AQ-13, a candidate antimalarial, and chloroquine in healthy volunteers. PLoS Clin Trials 2007;2:e6.
    OpenUrlCrossRefPubMed
  11. ↵
    1. Pukrittayakamee S,
    2. Tarning J,
    3. Jittamala P,
    4. et al
    . Pharmacokinetic interactions between primaquine and chloroquine. Antimicrob Agents Chemother 2014;58: 3354–9.
    OpenUrlAbstract/FREE Full Text
  12. ↵
    1. Ursing J,
    2. Rombo L,
    3. Eksborg S,
    4. et al
    . High-dose chloroquine for uncomplicated plasmodium falciparum malaria is well tolerated and causes similar QT interval prolongation as standard-dose chloroquine in children. Antimicrob Agents Chemother 2020 Feb. 21;64. pii: e01846-19. doi:10.1128/AAC.01846-19.
    OpenUrlAbstract/FREE Full Text
  13. ↵
    1. Juurlink DN
    . The cardiovascular safety of azithromycin. CMAJ 2014;186:1127–8.
    OpenUrlFREE Full Text
  14. ↵
    1. Fossa AA,
    2. Wisialowski T,
    3. Duncan JN,
    4. et al
    . Azithromycin/chloroquine combination does not increase cardiac instability despite an increase in monophasic action potential duration in the anesthetized guinea pig. Am J Trop Med Hyg 2007;77:929–38.
    OpenUrlAbstract/FREE Full Text
  15. ↵
    1. Sagara I,
    2. Oduro AR,
    3. Mulenga M,
    4. et al
    . Efficacy and safety of a combination of azithromycin and chloroquine for the treatment of uncomplicated Plasmodium falciparum malaria in two multi-country randomised clinical trials in African adults. Malar J 2014;13:458.
    OpenUrl
  16. ↵
    1. Chandramohan D,
    2. Dicko A,
    3. Zongo I,
    4. et al
    . Effect of adding azithromycin to seasonal malaria chemoprevention. N Engl J Med 2019;380:2197-206.
    OpenUrl
  17. ↵
    1. El-Solia A,
    2. Al-Otaibi K,
    3. Ai-Hwiesh AK
    . Hydroxychloroquine-induced hypoglycaemia in non-diabetic renal patient on peritoneal dialysis. BMJ Case Rep 2018 Apr. 18;2018. pii: bcr-2017-223639. doi:10.1136/bcr-2017-223639.
    OpenUrlAbstract/FREE Full Text
    1. Unübol M,
    2. Ayhan M,
    3. Guney E
    . Hypoglycemia induced by hydroxychloroquine in a patient treated for rheumatoid arthritis. J Clin Rheumatol 2011;17:46–7.
    OpenUrlPubMed
    1. Abu-Shakra M,
    2. Lee P
    . Hypoglycemia: an unusual adverse reaction to chloroquine. Clin Exp Rheumatol 1994;12:95.
    OpenUrlPubMed
  18. ↵
    1. Shojania K,
    2. Koehler BE,
    3. Elliott T
    . Hypoglycemia induced by hydroxychloroquine in a type II diabetic treated for polyarthritis. J Rheumatol 1999;26:195–6.
    OpenUrlPubMed
  19. ↵
    1. Powrie JK,
    2. Smith GD,
    3. Shojaee-Moradie F,
    4. et al
    . Mode of action of chloroquine in patients with non-insulin-dependent diabetes mellitus. Am J Physiol 1991; 260:E897–904.
    OpenUrl
  20. ↵
    1. Gupta A
    . Real-world clinical effectiveness and tolerability of hydroxychloroquine 400 mg in uncontrolled type 2 diabetes subjects who are not willing to initiate insulin therapy (HYQ-Real-World Study). Curr Diabetes Rev 2019;15:510–9.
    OpenUrl
  21. ↵
    1. Boyle PJ,
    2. Justice K,
    3. Krentz AJ,
    4. et al
    . Octreotide reverses hyperinsulinemia and prevents hypoglycemia induced by sulfonylurea overdoses. J Clin Endocrinol Metab 1993;76:752–6.
    OpenUrlCrossRefPubMed
  22. ↵
    1. Mohan D,
    2. Mohandas E,
    3. Rajat R
    . Chloroquine psychosis: A chemical psychosis? J Natl Med Assoc 1981;73:1073–6.
    OpenUrlPubMed
  23. ↵
    1. Aneja J,
    2. Goya D,
    3. Choudhary B
    . Psychosis consequent to antimalarial drug use in a young child. J Family Med Prim Care 2019;8:1781–3.
    OpenUrl
  24. ↵
    1. Bhatia MS
    . Chloroquine-induced psychiatric complications. Br J Psychiatry 1991;159:735.
    OpenUrlFREE Full Text
    1. Das P,
    2. Rai A,
    3. Chopra A,
    4. et al
    . Psychosis likely induced by hydroxychloroquine in a patient with chronic Q fever: a case report and clinically relevant review of pharmacology. Psychosomatics 2014;55:409–13.
    OpenUrlCrossRefPubMed
    1. Hsu W,
    2. Chiu N,
    3. Huang S
    . Hydroxychloroquine-induced acute psychosis in a systemic lupus erythematosus female. Acta Neuropsychiatr 2011;23:318–9.
    OpenUrlCrossRef
  25. ↵
    1. Kwak YT,
    2. Yang Y,
    3. Park SY
    . Chloroquine-associated psychosis mimicking very late-onset schizophrenia: case report. Geriatr Gerontol Int 2015;15:1096–7.
    OpenUrl
  26. ↵
    1. Maxwell NM,
    2. Nevin RL,
    3. Stahl S,
    4. et al
    . Prolonged neuropsychiatric effects following management of chloroquine intoxication with psychotropic polypharmacy. Clin Case Rep 2015;3:379–87.
    OpenUrl
  27. ↵
    1. Mohammad S,
    2. Clowse MEB,
    3. Eudy AM,
    4. et al
    . Examination of hydroxychloroquine use and hemolytic anemia in G6PDH-deficient patients. Arthritis Care Res (Hoboken) 2018;70:481–5.
    OpenUrl
  28. ↵
    1. Lee JY,
    2. Vinayagamoorthy N,
    3. Han K,
    4. et al
    . Association of polymorphisms of cytochrome P450 2D6 with blood hydroxychloroquine levels in patients with systemic lupus erythematosus. Arthritis Rheumatol 2016;68:184–90.
    OpenUrl
  29. ↵
    1. Zhou SF
    . Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I. Clin Pharmacokinet 2009;48:689–723.
    OpenUrlCrossRefPubMed
  30. ↵
    1. Neafsey P,
    2. Ginsberg G,
    3. Hattis D,
    4. et al
    . Genetic polymorphism in cytochrome P450 2D6 (CYP2D6): population distribution of CYP2D6 activity. J Toxicol Environ Health B Crit Rev 2009;12:334–61.
    OpenUrlCrossRefPubMed
  31. ↵
    1. Chamnanphon M,
    2. Gaedigk A,
    3. Puangpetch A,
    4. et al
    . Pharmacogene sariation in Thai Plasmodium vivax relapse patients treated with a combination of primaquine and chloroquine. Pharmgenomics Pers Med 2020;13:1–12.
    OpenUrl
  32. ↵
    1. Elewa H,
    2. Wilby KJ
    . A review of pharmacogenetics of antimalarials and associated clinical implications. Eur J Drug Metab Pharmacokinet 2017;42:745–56.
    OpenUrl
  33. ↵
    1. Masimirembwa CM,
    2. Hasler JA,
    3. Johansson I
    . Inhibitory effects of antiparasitic drugs on cytochrome P450 2D6. Eur J Clin Pharmacol 1995;48:35–8.
    OpenUrlPubMed
  34. ↵
    1. Somer M,
    2. Kallio J,
    3. Pesonen U,
    4. et al
    . Influence of hydroxychloroquine on the bioavailability of oral metoprolol. Br J Clin Pharmacol 2000;49:549–54.
    OpenUrlCrossRefPubMed
  35. ↵
    1. Kirchheiner J,
    2. Keulen JT,
    3. Bauer S,
    4. et al
    . Effects of the CYP2D6 gene duplication on the pharmacokinetics and pharmacodynamics of tramadol. J Clin Psychopharmacol 2008;28:78–83.
    OpenUrlCrossRefPubMed
  36. ↵
    1. Terkeltaub RA,
    2. Furst DE,
    3. Digiacinto JL,
    4. et al
    . Novel evidence-based colchicine dose-reduction algorithm to predict and prevent colchicine toxicity in the presence of cytochrome P450 3A4/P-glycoprotein inhibitors [published erratum in Arthritis Rheum 2011;63:3521]. Arthritis Rheum 2011;63:2226–37.
    OpenUrlCrossRefPubMed
  37. ↵
    1. Leckie MJ,
    2. Rees RG
    . Stevens–Johnson syndrome in association with hydroxychloroquine treatment for rheumatoid arthritis. Rheumatology (Oxford) 2002;41:473–4.
    OpenUrlCrossRefPubMed
  38. ↵
    1. Cameron MC,
    2. Word AP,
    3. Dominguez A
    . Hydroxychloroquine-induced fatal toxic epidermal necrolysis complicated by angioinvasive rhizopus. Dermatol Online J 2014 Nov. 15;20. pii: 13030/qt1q90q0h5.
  39. ↵
    1. Murphy M,
    2. Carmichael AJ
    . Fatal toxic epidermal necrolysis associated with hydroxychloroquine. Clin Exp Dermatol 2001;26:457–8.
    OpenUrlCrossRefPubMed
  40. ↵
    1. Girijala RL,
    2. Siddiqi I,
    3. Kwak Y,
    4. et al
    . Pustular DRESS syndrome secondary to hydroxychloroquine with EBV reactivation. J Drugs Dermatol 2019;18:207–9.
    OpenUrl
  41. ↵
    1. Volpe A,
    2. Marchetta A,
    3. Caramaschi P,
    4. et al
    . Hydroxychloroquine-induced DRESS syndrome. Clin Rheumatol 2008;27:537–9.
    OpenUrlCrossRefPubMed
  42. ↵
    1. Dashraath P,
    2. Jing Lin Jeslyn W,
    3. Mei Xian Karen L,
    4. et al
    . Coronavirus disease 2019 (COVID-19) pandemic and pregnancy. Am J Obstet Gynecol 2020 Mar. 23 [Epub ahead of print]. pii: S0002-9378(20)30343-4. doi:10.1016/j.ajog.2020.03.021.
    OpenUrlCrossRef
  43. ↵
    1. Sarkar M,
    2. Woodland C,
    3. Koren G,
    4. et al
    . Pregnancy outcome following gestational exposure to azithromycin. BMC Pregnancy Childbirth 2006;6:18.
    OpenUrlCrossRefPubMed
  44. ↵
    1. Yusuf IH,
    2. Sharma S,
    3. Luqmani R,
    4. et al
    . Hydroxychloroquine retinopathy. Eye (Lond) 2017;31:828–45.
    OpenUrl
    1. Stein M,
    2. Bell MJ,
    3. Ang LC
    . Hydroxychloroquine neuromyotoxicity. J Rheumatol 2000;27:2927–31.
    OpenUrlPubMed
  45. ↵
    1. Chatre C,
    2. Roubille F,
    3. Vernhet H,
    4. et al
    . Cardiac complications attributed to chloroquine and hydroxychloroquine: a systematic review of the literature. Drug Saf 2018;41:919–31.
    OpenUrl
  46. ↵
    1. de Olano J,
    2. Howland MA,
    3. Su MK,
    4. et al
    . Toxicokinetics of hydroxychloroquine following a massive overdose. Am J Emerg Med 2019;37:2264.e5–2264.e8.
    OpenUrl
  47. ↵
    1. Guastalegname M,
    2. Vallone A
    . Could chloroquine/hydroxychloroquine be harmful in coronavirus disease 2019 (COVID-19) treatment? Clin Infect Dis 2020 Mar. 24 [Epub ahead of print]. pii: ciaa321. doi:10.1093/cid/ciaa321.
    OpenUrlCrossRef
  48. ↵
    1. Silverman E
    . Teva and Mylan to jumpstart production of old malaria drug to fight the novel coronavirus. 2020 Mar. 19. STAT [Boston]. Available: https://www.statnews.com/pharmalot/2020/03/19/teva-mylan-coronavirus-covid19-malaria/ (accessed 2020 Mar. 30).
PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 192 (17)
CMAJ
Vol. 192, Issue 17
27 Apr 2020
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection
David N. Juurlink
CMAJ Apr 2020, 192 (17) E450-E453; DOI: 10.1503/cmaj.200528

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection
David N. Juurlink
CMAJ Apr 2020, 192 (17) E450-E453; DOI: 10.1503/cmaj.200528
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • What are the potential adverse effects of chloroquine or hydroxychloroquine and azithromycin?
    • Could use of these drugs potentially worsen COVID-19?
    • Could use of these drugs to treat or prevent COVID-19 lead to shortages for other patients?
    • Conclusion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Tables
  • Related Content
  • Responses
  • Metrics
  • PDF

Related Articles

  • Additional safety consideration for azithromycin in the management of SARS-CoV-2 infection
  • Considérations pour la prise en charge sécuritaire d’une infection au SRAS-CoV-2 au moyen de chloroquine, d’hydroxychloroquine et d’azithromycine
  • PubMed
  • Google Scholar

Cited By...

  • New prophylaxis regimen for SARS-CoV-2 infection in health professionals with low doses of hydroxychloroquine and bromhexine: a randomised, double-blind placebo clinical trial (ELEVATE Trial)
  • Torsades de pointes in SARS-CoV-2 (COVID-19) pneumonia: medicine reconciliation and careful monitoring of QTc interval may help prevent cardiac complications
  • Mental health of healthcare workers during early phase of COVID19: Variable performance on different factors of stress
  • Effectiveness and Safety of Chloroquine or Hydroxychloroquine as a mono-therapy or in combination with Azithromycin in the treatment of COVID-19 patients: Systematic Review and Meta-Analysis
  • Chloroquine and hydroxychloroquine effectiveness in human subjects during coronavirus: a systematic review
  • Outcomes and clinical practice in patients with COVID-19 admitted to the intensive care unit in Montreal, Canada: a descriptive analysis
  • Controversies over hydroxychloroquine in the prevention of SARS-CoV-2 infection put rheumatologists on the frontline
  • Hydroxychloroquine increased psychiatric-like behaviors and disrupted the expression of related genes in the mouse brain
  • Rapid in vitro assays for screening neutralizing antibodies and antivirals against SARS-CoV-2
  • Potential Antiviral Drugs for SARS-Cov-2 Treatment: Preclinical Findings and Ongoing Clinical Research
  • Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection
  • Google Scholar

More in this TOC Section

  • Pharmacologic prevention of migraine
  • Diagnosis and acute management of migraine
  • Transient ischemic attack and minor stroke: diagnosis, risk stratification and management
Show more Review

Similar Articles

Collections

  • Topics
    • Infectious diseases: COVID-19

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • CPD credits
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
  • Accessibiity
  • CMA Civility Standards
CMAJ Group

Copyright 2023, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: cmajgroup@cmaj.ca

Powered by HighWire